Hemab Therapeutics Holdings Inc., a clinical-stage biotechnology company, is seeking to raise as much as $212 million in a US initial public offering.
The firm, which counts Novo Nordisk Foundation as one of its biggest investors, is offering 11.8 million shares at $16 to $18 each, according to its filing Monday with the US Securities and Exchange Commission. At the top of the price range, the Cambridge, Massachusetts-based company would have a market value of about $705.7 million, based on the outstanding shares listed in the filing.
Hemab is developing therapies for blood coagulation disorders such as Glanzmann thrombasthenia ...
